Back to Search
Start Over
Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect – a glimpse to the future
- Source :
- Expert Opinion on Investigational Drugs. 27:569-572
- Publication Year :
- 2018
- Publisher :
- Informa UK Limited, 2018.
-
Abstract
- In the last years, a remarkable progress has been made in the clinical application of novel immunotherapy agents, the so called 'checkpoint inhibitors,' that has revolutionized the treatment of many malignant tumors. Their design has been based on the immune-mediated mechanisms of antitumor activity circle, such as antigen release and presentation, activation and trafficking of T-cells into tumors, depletion of immunosuppression, and immunogenic cell death. Various combinations of checkpoint inhibitors are being designed and/or tested, such as double checkpoint blockade, combination with chemotherapy, radiotherapy, molecularly targeted agents, and other immune-directed strategies.
- Subjects :
- 0301 basic medicine
T-Lymphocytes
medicine.medical_treatment
Immune checkpoint inhibitors
03 medical and health sciences
0302 clinical medicine
Neoplasms
Antineoplastic Combined Chemotherapy Protocols
medicine
Animals
Humans
Pharmacology (medical)
Molecular Targeted Therapy
Pharmacology
Chemotherapy
business.industry
Cancer
Immunosuppression
General Medicine
Immunotherapy
medicine.disease
Combined Modality Therapy
Blockade
Radiation therapy
030104 developmental biology
Drug Design
030220 oncology & carcinogenesis
Cancer research
Immunogenic cell death
business
Subjects
Details
- ISSN :
- 17447658 and 13543784
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Investigational Drugs
- Accession number :
- edsair.doi.dedup.....9027ad8eee8fa0cc4649d7752bb59168